This presentation summarizes recommendations from an ISPE working group for assessing blend and content uniformity. The group proposed modifications to address issues with the withdrawn 2002 FDA guidance. Key recommendations include a two-stage blend testing approach using statistical analysis and flexibility in selecting sampling plans, acceptance criteria, and confidence/coverage levels using a risk-based approach.
This presentation highlights the reasons which lead to the withdrawal of the 2002 Guidance of the FDA and the current issue with Blend Uniformity and Content Uniformity Determinations.
The presentation will give an insight into ICH Q1A Stability testing of New drug products. Here the ppt is much focused on stability requirements for ANDA, no: of batches, storage conditions, testing frequency.
This presentation highlights the reasons which lead to the withdrawal of the 2002 Guidance of the FDA and the current issue with Blend Uniformity and Content Uniformity Determinations.
The presentation will give an insight into ICH Q1A Stability testing of New drug products. Here the ppt is much focused on stability requirements for ANDA, no: of batches, storage conditions, testing frequency.
OOS and OOT investigation is always a challenging task. This slide may help for a better understanding of investigation procedure according to regulatory requrement.
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
WHO has recently issued draft document titled "Guidelines on Validation". These guidelines (i.e., the main text included in this working document) cover the general principles of validation and qualification.
These guidelines focus mainly on the overall concept of validation and are not intended to be prescriptive in specific validation requirements. This document serves as general guidance only and the principles may be considered useful in its application in the manufacture and control of starting materials and finished pharmaceutical products (FPPs), as well as other areas. Validation of specific processes and systems, for example, in sterile product manufacture, requires much more consideration and a detailed approach that is beyond the scope of this document. The general text in this document may be applicable to validation and qualification of premises, equipment, utilities, systems, processes, and procedures.
The draft on the specific topics, the appendices to this main text, will follow. The following is an overview on the appendices that are intended to complement the text of this working document:
Appendix 1: Validation of heating, ventilation and air-conditioning systems - will be replaced by cross reference to WHO Guidelines on GMP for HVAC systems for considerations in qualification of HVAC systems (update - working document QAS/15.639/Rev. 1)
Appendix 2: Validation of water systems for pharmaceutical use - will be replaced by cross-reference to WHO Guidelines on water for pharmaceutical use for consideration in qualification of water purification systems
Appendix 3: Cleaning validation - consensus to retain
Appendix 4: Analytical method validation - update in process
Appendix 5: Validation of computerized systems - update in process
Appendix 6: Qualification of systems and equipment - update in process
Appendix 7: Non-sterile process validation - update already published as Annex 3, WHO Technical Report Series, No. 992, 2015
Comments on this draft document are due by July 12, 2016.
A presentation on this guidance is given below:
Presentation on New WHO Guidance on Validations
European Medicines Agency has issued a new guidelines describing stability testing requirements for variations to a marketing authorisation after approval, setting out the differing requirements for changes to active pharmaceutical ingredients (API) and finished dosage form production.
Manufacturers in the EU making changes to their manufacturing processes will have to submit additional stability data, according to these new guidelines.
This presentation is compiled by “ Drug Regulations” from freely available resources like the FDA on the World wide web.
“Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals.
This guideline is a revised of the ICHQ1A –stability data package for new drug substance /DRUG PRODUCT .The [urpose of guideline to define stability data package that sufficient for a registration application within the 3 regions of EU ,JAPAN & USA & to maintain the quality of drug products, in relation to safety , efficacy & acceptability throughout the propose shelf life.
FDA Process Validation Guidance (Guidance for Industry: Process Validation- General Principles and Practices, Jan. 2011) outlines process validation activities in three stages - Stage 1: Process Design, Stage 2: Process Qualification and Stage 3: Continued Process Verification. Completion of Stage 2 subsequent to Stage 1 is a major milestone in the Process Validation Lifecycle as it confirms the process design and demonstrates the expected consistent performance of the manufacturing process. Knowledge and information gained from the design stage through the process qualification stage is used to complete this assessment. Stage 2 demonstrates suitability for successful commercial distribution where the data indicates that the process meets the conditions established in the protocol. Continued Process Verification is initiated for the subsequent commercial batches. Stage 3 assures that the process remains in a state of control during commercial manufacture.
This presentation gives a practical approach to implement the stage 3 of the FDA Process Validation Guide.
OOS and OOT investigation is always a challenging task. This slide may help for a better understanding of investigation procedure according to regulatory requrement.
In the last year or so the FDA and the EMA have issued new guidance/ draft guidance on "Process Validation".These align process validation activities with a product lifecycle concept and the International Conference on Harmonisation (ICH) guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The earlier guidelines were developed before the elaboration of the new ICH guidelines.With these new guidelines, additional opportunities are available to verify the control of the process by alternative means to the manufacture of traditional process validation batches. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process and the control strategy. ICH Q8 refers to an ‘enhanced’ approach to pharmaceutical development which includes an alternative to the traditional process validation.
Continuous process verification [see definition in ICH Q8(R2) glossary] can be utilised in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
There is now a new paradigm in process validation. This presentation has been prepared from material available from FDA , EMA and ICH for beginners to have an overview of the new paradigm.
WHO has recently issued draft document titled "Guidelines on Validation". These guidelines (i.e., the main text included in this working document) cover the general principles of validation and qualification.
These guidelines focus mainly on the overall concept of validation and are not intended to be prescriptive in specific validation requirements. This document serves as general guidance only and the principles may be considered useful in its application in the manufacture and control of starting materials and finished pharmaceutical products (FPPs), as well as other areas. Validation of specific processes and systems, for example, in sterile product manufacture, requires much more consideration and a detailed approach that is beyond the scope of this document. The general text in this document may be applicable to validation and qualification of premises, equipment, utilities, systems, processes, and procedures.
The draft on the specific topics, the appendices to this main text, will follow. The following is an overview on the appendices that are intended to complement the text of this working document:
Appendix 1: Validation of heating, ventilation and air-conditioning systems - will be replaced by cross reference to WHO Guidelines on GMP for HVAC systems for considerations in qualification of HVAC systems (update - working document QAS/15.639/Rev. 1)
Appendix 2: Validation of water systems for pharmaceutical use - will be replaced by cross-reference to WHO Guidelines on water for pharmaceutical use for consideration in qualification of water purification systems
Appendix 3: Cleaning validation - consensus to retain
Appendix 4: Analytical method validation - update in process
Appendix 5: Validation of computerized systems - update in process
Appendix 6: Qualification of systems and equipment - update in process
Appendix 7: Non-sterile process validation - update already published as Annex 3, WHO Technical Report Series, No. 992, 2015
Comments on this draft document are due by July 12, 2016.
A presentation on this guidance is given below:
Presentation on New WHO Guidance on Validations
European Medicines Agency has issued a new guidelines describing stability testing requirements for variations to a marketing authorisation after approval, setting out the differing requirements for changes to active pharmaceutical ingredients (API) and finished dosage form production.
Manufacturers in the EU making changes to their manufacturing processes will have to submit additional stability data, according to these new guidelines.
This presentation is compiled by “ Drug Regulations” from freely available resources like the FDA on the World wide web.
“Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals.
This guideline is a revised of the ICHQ1A –stability data package for new drug substance /DRUG PRODUCT .The [urpose of guideline to define stability data package that sufficient for a registration application within the 3 regions of EU ,JAPAN & USA & to maintain the quality of drug products, in relation to safety , efficacy & acceptability throughout the propose shelf life.
FDA Process Validation Guidance (Guidance for Industry: Process Validation- General Principles and Practices, Jan. 2011) outlines process validation activities in three stages - Stage 1: Process Design, Stage 2: Process Qualification and Stage 3: Continued Process Verification. Completion of Stage 2 subsequent to Stage 1 is a major milestone in the Process Validation Lifecycle as it confirms the process design and demonstrates the expected consistent performance of the manufacturing process. Knowledge and information gained from the design stage through the process qualification stage is used to complete this assessment. Stage 2 demonstrates suitability for successful commercial distribution where the data indicates that the process meets the conditions established in the protocol. Continued Process Verification is initiated for the subsequent commercial batches. Stage 3 assures that the process remains in a state of control during commercial manufacture.
This presentation gives a practical approach to implement the stage 3 of the FDA Process Validation Guide.
This presentation correlates the requirements of Annex 11 guidelines to other official regulations and guidance documents.
The correlation is organized in a tabular format.
In the row lists the contents of Annex 11 together with the paragraph numbers.
Rest of the rows correlate the section numbers of
Annex 11 Versions 1993
US FDA 21 CFR Part 211
US FDA Part 820 and
US FDA 21 CFR Part 11
Types of validation & validation of specific dosage.pptxankitanakashe21
Validation is a proven assurance of the process efficiency and sturdiness, and it is the full-fledged quality control tool for the pharmaceutical industries. It eliminates the chances of batch failures as the products are manufactured as per pre optimization of each manufacturing steps. The conventional process of testing at last stage created much problems in maintaining the uniformity of each batch but with the introduction of concept of validation, it has been easy to maintain the batch uniformity of the product along with imparting quality in them.
Effective handling of OOS investigations involves adhering to OOS investigation guidelines to ensure thorough analysis and resolution. Following robust protocols and regulatory standards in OOS investigation processes is crucial for maintaining product quality and compliance.
Read more here https://www.ipa-india.org/wp-content/uploads/2023/05/Presentation-on-Handling-OOS-Investigations-Regulatory-Expectations-Dipesh-Shah-Comsumer-Safety-Officer-USFDA.pdf
Stages of scale up process mparm 1st year pharmaceutical process chemistryDhanashreeSarwan
Define Scale up process, need of Scale up technique, Stages of scale up process Bench\lab scale, pilot plant, large scale up technique, validation of large scale up process
Environmental Monitoring describes the microbiological testing under- taken in order to detect changing trends of microbial counts and micro- flora growth within cleanroom or controlled environments. The results obtained provide information about the physical construction of the room, the performance of the Heating, Ventilation, and Air-Conditioning (HVAC) system, personnel cleanliness, gowning practices, the equipment, and cleaning operations.
Over the past decade, environmental monitoring has become more sophisticated in moving from random sampling, using an imaginary grid over the room and testing in each grid, to the current focus on risk assessment and the use of risk assessment tools to determine the most appropriate methods for environmental monitoring.
This presentation gives current trends in the application of risk assessment to the practice of environmental monitoring.
This presentation is compiled from freely available resources like the websites of FDA, EMA ,WHO and research papers published by experts in this field like Sandle, T Reinmüller, B , Hyde, W,, Costello, E.K., Lauber, C. L., Hamady, M., Fierer, N., Gordon, J.I., Knight, R.
Paper published by T. Sandle on clean room contamination was referred extensively for this presentation. “Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals.
This presentation gives an overview of : Validation of microbiological methods , Considering some of the limitations and
Key criteria that may be applicable for assessment.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Blend and Content Uniformity : Industry Recommendations for Way Forward
1. This presentation is compiled by “ Drug Regulations”
a non profit organization which provides free online
resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest
information from the world of Pharmaceuticals.
2. This presentation is compiled from freely available resource like
the website of FDA & ISPE specifically a paper of ISPE
titled
“Paper published Garcia, Thomas et.al., Recommendations for the
assessment of blend and content uniformity: modifications to withdrawn
FDA draft stratified sampling guidance, J Pharm Innov, 2014, (DOI)
10.1007/s12247-014-9207-0.”
“Drug Regulations” is a non profit organization which provides free
online resource to the Pharmaceutical Professional.
Visit Our Website GMP Training
for latest information from the world of Pharmaceuticals.
02-09-2016 2
Visit Our WEBSITE GMP Training
http://fdagmp.blogspot.in/
3. This presentation highlights
◦ The reasons which lead to the withdrawal
of the 2002 Guidance of the FDA
◦ The current Industry Consensus as
represented by the ISPE BUCU group
02-09-2016 3Visit Our Website GMP Training
4. This presentation is based on following
paper published by the ISPE BUCU group
◦ “Garcia, Thomas et.al., Recommendations for the
assessment of blend and content uniformity:
modifications to withdrawn FDA draft stratified
sampling guidance, J Pharm Innov, 2014, (DOI)
10.1007/s12247-014-9207-0.”
02-09-2016 4Visit Our Website GMP Training
5. FDA withdrew draft guidance
◦ “Powder Blends and Finished Dosage Units – Stratified In-
Process Dosage Unit Sampling and Assessment” on August
7, 2013
Following Sections were no longer consistent with
current FDA Thinking
◦ Section V (Exhibit/Validation Batch Powder Mix
Homogeneity) and
◦ Section VII (Routine Manufacturing Batch Testing Methods)
02-09-2016 5Visit Our Website GMP Training
6. Section V recommended that 3 replicate blend samples be taken
from at least 10 locations, but no requirement to test all replicates
Preference to test all replicate samples to allow variance component
analysis of the data
High between location variability implies the blend is not
homogenous
Acceptance criteria Section VII were based on limits stated in USP
General Chapter
◦ <905> Uniformity of Dosage Units
02-09-2016 6Visit Our Website GMP Training
7. USP <905> does not use a statistical sampling plan
Results provide limited statistical assurance that future
samples from the batch would pass
FDA no longer supports the approach stated in the withdrawn
guidance document, nor the use of USP <905> for batch
release
Created a gap for manufacturers & products that use
traditional blend & dosage unit uniformity approaches for
process validation & commercial batch release
02-09-2016 7Visit Our Website GMP Training
8. Formed in August 2013 to discuss approaches to assess blend
and content uniformity
Sponsored by the International Society for Pharmaceutical
Engineering (ISPE)
Session at ISPE Annual Meeting (November 6, 2013) covering the
current issues associated with blend and content uniformity
analysis
◦ FDA concerns with current practices
◦ Importance of using statistically sound sampling plans and acceptance criteria
Consider the impact that therapeutic properties of the drug can
have on content uniformity acceptance criteria
02-09-2016 8Visit Our Website GMP Training
10. Modifications are proposed by the Group to assess “adequacy of mixing to
assure uniformity and homogeneity” of the finished product in accordance
with CGMP requirement 21 CFR 211.110 (7)
Blend sampling and testing plans are revised to be more explicit
Statistical approaches and sampling plans provide more confidence that
future samples from the batch will comply with USP <905>.
Flexible risk based approach to define the number of dosage units to be
tested during routine manufacture
◦ Balance consumer’s risk and producer s risk
◦ Approach can be applied to all stages of process validation
Can use for various dosage forms for which USP <905> applies
◦ Tablets, capsules (all types), sachets, powder filled bottles and in some instances semisolids,
regardless of drug loading.
02-09-2016 10Visit Our Website GMP Training
11. Satisfies CGMP and application review requirements for in- process and
release testing to demonstrate adequacy of the powder mix and uniform
content of the dosage units
Multiple approaches, sampling plans and acceptance criteria can be used
to assess blend and/or dosage unit uniformity, including:
Various statistical approaches that use confidence intervals and/or
tolerance intervals that provide assurance of complying with USP <905>
The application of PAT sensors to determine uniformity of powder mix
and blending end points
The application of PAT and large n acceptance criteria to demonstrate
uniformity of dosage units
02-09-2016 11Visit Our Website GMP Training
12. Retains the use in-process dosage unit data as a surrogate measure
for blend uniformity and release testing of the drug product during
commercial production
The identification of blending parameters and assessment of blend
homogeneity throughout the blender and/or intermediate bulk
containers using appropriate sampling plans
Sampling Technique and procedure:
Assess impact of blend sample size (e.g., 1-10X dosage unit range;
sizes > 3X can be used with adequate justification)
02-09-2016 12Visit Our Website GMP Training
13. Sampling errors should be identified, which may be negated by the use
of in- situ analytical techniques using real-time sampling and analysis
Design sampling plans and evaluate the data using appropriate
statistical analysis, such as variance component analysis to measure
variability present in the results
Include significant events (start-up, end of run, bin change-over
samples)
Low dose / high potency drugs may require more rigorous sampling
plans
Compare blend, in-process dosage units, and finished product data to
justify the use of in-process dosage units to demonstrate blend and
content uniformity for finished product release
02-09-2016 13Visit Our Website GMP Training
15. [Example Sampling Plan]
Take at least 3 blend samples from at least 10 locations in the
blender
Stage 1 Blend Testing:
◦ Assay 1 sample from each location and calculate the standard deviation (SD) for the
samples
SD ≤ 3.0% of target, blend uniformity is acceptable; proceed to
Stage 1 dosage unit testing
SD is >3.0% of target, proceed to Stage 2 blend testing
02-09-2016 15Visit Our Website GMP Training
16. Stage 2 Blend Testing:
◦ Assay the replicate blend samples from each location and calculate the SD for the samples
SD ≤ 3.0%, blend uniformity is acceptable; proceed to Stage 1 dosage
unit testing. VCA not required
SD 3.1% - 5.0% (inclusive), blend uniformity is acceptable; proceed to
Stage 2 dosage unit testing; recommend performing VCA for the blend
and dosage unit data
SD > 5.0%, conduct an investigation, including VCA
If the high SD is attributed to a sampling/assay error, proceed to Stage 2
dosage unit testing
If the high SD is attributed to a product/process related cause, the blend
uniformity is unacceptable
02-09-2016 16Visit Our Website GMP Training
17. [Example Sampling Plan]
Sample at least 3 in-process dosage units from at least 40 approximately equally
spaced predetermined locations throughout the batch (including the beginning
and end of the run)
2. Assay at least 3 dosage units per location from at least 20 (of the 40)
predetermined locations (including the beginning and end of the run); values
should not be weight corrected
3. Determine if:
◦ All individual values between 75.0-125.0% (non-weight corrected)
◦ Data complies with the acceptance criteria for the statistical approach, sample size and confidence
& coverage selected
◦ If the results comply with, blend and dosage unit uniformity is demonstrated
◦ If either of the above acceptance criteria are not met, proceed to Stage 2 testing
02-09-2016 17Visit Our Website GMP Training
18. Assay at least 3 dosage units per location from the remaining 20 locations
that were not tested during Stage 1
Determine if the data comply with the acceptance criteria:
◦ All individual values between 75.0-125.0% (non-weight corrected)
◦ Data complies with the acceptance criteria for the statistical approach, sample size and confidence
& coverage selected
◦ If data complies with above, blend & dosage unit uniformity is demonstrated
◦ If not, the blend and/or dosage units are not uniform
For products requiring Stage 2 testing, consider performing VCA on the
combined (Stage 1 and Stage 2) dosage unit data to identify potential
sources of variability that can lead to process improvements
02-09-2016 18Visit Our Website GMP Training
19. Manufacturer decides what statistical approach, sampling
plan, acceptance criteria and levels of confidence and
coverage to use during Continued Process Verification to
provide assurance in passing USP <905>
◦ Based on the levels of producer and consumer risks they are willing to
accept
◦ If the in-process dosage unit data is used as a surrogate test for blend
uniformity and batch release (non-weight corrected data), a systematic
sampling plan should be used to identify the position of sampling
locations
02-09-2016 19Visit Our Website GMP Training
21. Sample one in-process dosage unit from 30 locations
throughout the compression or filling process including
beginning and end of run samples
Locations must be across the entire batch, including
beginning and end (i.e. not just a random sample)
Stage 1 Testing: Assay 1 dosage unit from at least 10 of the
30 sampling locations
02-09-2016 21Visit Our Website GMP Training
22. Determine if acceptance criteria are met
◦ All individual values between 75.0-125.0% (non-weight corrected)
◦ If the results comply with the acceptance criteria for the statistical
approach, sample size and levels of confidence & coverage selected.
◦ If the results comply, blend and dosage unit uniformity is demonstrated
◦ If either of the above acceptance criteria are not met, proceed to Stage 2
testing
02-09-2016 22Visit Our Website GMP Training
23. Test the remaining 20 dosage units Determine is acceptance
criteria are met
◦ All individual values should be between 75.0-125.0% (non-weight
corrected)
◦ The data complies with the acceptance criteria for the statistical approach,
sample size and levels of confidence & coverage selected
◦ If the data comply, blend and dosage unit uniformity is demonstrated
◦ If the data does not comply, the dosage units and possibly the blend are
not uniform
02-09-2016 23Visit Our Website GMP Training
24. For products with blend SDs 3.1-5.0% and/or required Stage 2
dosage unit testing during Process Qualification:
◦ Additional samples may be needed during Continued Process Verification (Stage
3A)
◦ Number of dosage units assayed should be risk based • Higher SDs (4.0-
5.0%) comparable to Process Qualification
Stage 2 quantities
◦ Moderate SDs (3.1-4.0%) comparable to Process Qualification Stage 2
quantities.
◦ Quantities tested can be reduced if:
◦ Process changes improve blend and/or dosage unit uniformity
◦ A due diligence effort fails to improve the process resulting in high but
consistent (and acceptable) SDs, indicating its the best the process can do
02-09-2016 24Visit Our Website GMP Training
25. Blend uniformity analysis should be performed during Process
Design and Process Qualification batches
◦ Do not skip blend uniformity testing and default directly to dosage units
◦ BUA can be performed for any mixing operation, although the final blend
(lubricated) is the best indicator prior to compression or filling
Fewer sampling locations may be justified for smaller scale
batches (e.g., early Process Design batches; small Process
Qualification and commercial batch sizes)
02-09-2016 25Visit Our Website GMP Training
26. Sample at least 3 blend samples and at least 3 dosage units
from each location
Revised sampling plans must be appropriate for assuring
acceptable blend and dosage unit uniformity
Acceptance criteria may be adjusted to be phase appropriate
(especially during Process Design)
Situations may exist where it is not possible to sample blends
◦ e.g., Potent drugs manufactured in high containment equipment
(significant operator safety risks)
02-09-2016 26Visit Our Website GMP Training
27. Recommend a 2-stage approach for the assessment of blend
uniformity – Unnecessary to assay blend replicates if SD ≤
3.0% for the first set of samples
Total SD, between location and within location variance
components would be very small
If SD > 3.0%, VCA information could identify sources of
variability, and opportunities to improve blend uniformity
◦ Weight correction is justified when using dosage unit content uniformity
as a surrogate test to demonstrate blend uniformity
02-09-2016 27Visit Our Website GMP Training
28. ◦ In-process dosage units must be sampled over the entire batch to assure
the entire blender is uniform, including beginning and end of run
Weight correction is not allowed when using dosage unit
content uniformity data for batch release
If the in-process dosage unit is not the final dosage form
(e.g., tablet core versus film coated tablet) demonstrate
content uniformity is not significantly impacted during
subsequent unit operations (e.g., film coating)
02-09-2016 28Visit Our Website GMP Training
29. Blend SD of 3.1 - 5.0%
◦ Blend uniformity is acceptable, but proceed to Stage 2 in-process dosage unit testing
◦ Group recommends performing VCA on the blend and dosage unit data to assess between location
and within location variance components to identify opportunities to improve blend uniformity
Blend SD >5.0%
◦ Conduct an investigation (including VCA) to determine if the variability was due to a non-blending
issue (e.g., sampling bias, analytical error or other non-formulation/process causes)
◦ Compare blend and dosage unit variance components
◦ If an error can be demonstrated and justified, implement corrective measures and proceed to Stage
2 dosage unit testing
◦ If the high SD is product/process related, then blend uniformity is unacceptable and further
formulation and/or process development is required for the product
02-09-2016 29Visit Our Website GMP Training
30. VCA recommended if SD for the blend and/or dosage units is >3%
◦ VCA results for blend and dosage unit data can identify potential opportunities to reduce variability, including if the
source of the variability is due to product/process issues or sampling/assay error
◦ Significant within-location variance in the blend data:
Variability may be due to poor micro-mixing and/or agglomeration
◦ Can carry over to the dosage units
Sampling error
◦ Sampling errors of the blend will not carry over to the dosage units
◦ Significant between-location variance
◦ Non-uniformity throughout the blender – Blending operation is not optimized
◦ Segregation has occurred
◦ Plot the data to help diagnose the problem
02-09-2016 30Visit Our Website GMP Training
31. Framework provides flexibility to use the preferred
statistical approach and acceptance criteria when
assessing content uniformity of the dosage units,
with justification
◦ Applicant must demonstrate why the sampling plan, statistical
approach and acceptance criteria selected are appropriate for
ensuring drug product content uniformity, and future samples
taken from the batch will have a high probability of passing USP
<905>
02-09-2016 31Visit Our Website GMP Training
32. Confidence and coverage levels should be selected
using a risk based approach
◦ Balance consumer’s and producer’s risks
◦ Consider other factors such as the therapeutic index of the
drug – Confidence/coverage levels should be fit for purpose
◦ Especially for Stage 1 Process Design; many statistical
approaches may be too discriminating for drug products in
development
02-09-2016 32Visit Our Website GMP Training
33. Consider Pharmacokinetic characteristics of the drug when
defining acceptance criteria for dosage unit uniformity
Drugs with high potency and/or narrow therapeutic indices
may require tighter acceptance criteria to reduce consumer
risk
Drugs with wide therapeutic indices can tolerate broader
acceptance criteria and minimize producer’s risk
An assessment of in vivo impact of the dosing unit precision
can be obtained by conducting pharmacokinetic simulations
employing a target potency distribution as an input (6, 12)
02-09-2016 33Visit Our Website GMP Training
34. Multiple statistical approaches, sampling plans and
acceptance criteria can be inserted within the framework to
provide confidence in passing USP <905>
Modifications to the original draft stratified sampling
guidance document (based on the framework) can fill the void
created by its withdrawal
The approach is scientifically justified, especially for products
that use traditional analytical techniques to assess adequacy
of powder mix and dosage unit uniformity
02-09-2016 34Visit Our Website GMP Training
35. This presentation is compiled from freely available resource like
the website of FDA & ISPE specifically a paper of ISPE
titled
“Paper published Garcia, Thomas et.al., Recommendations for the
assessment of blend and content uniformity: modifications to withdrawn
FDA draft stratified sampling guidance, J Pharm Innov, 2014, (DOI)
10.1007/s12247-014-9207-0.”
“Drug Regulations” is a non profit organization which provides free
online resource to the Pharmaceutical Professional.
Visit Our Website GMP Training
for latest information from the world of Pharmaceuticals.
02-09-2016 35
Visit Our WEBSITE GMP Training
http://fdagmp.blogspot.in/